Bandingkan Harga & Kinerja Intanwijaya Internasional Tbk (INCI) vs Organon Pharma Indonesia Tbk. (SCPI)
Kinerja harga (24 Jam Terakhir)
Statistik utama
Statistik utama
Perbedaan Intanwijaya Internasional Tbk dan Organon Pharma Indonesia Tbk.: Intanwijaya Internasional Tbk diperdagangkan di Rp800 (kapitalisasi pasar 167,16 M, volume 24 jam 43,7 rb), sedangkan Organon Pharma Indonesia Tbk. diperdagangkan di Rp29.000 (kapitalisasi pasar 104,4 M). Perbedaan utamanya: Intanwijaya Internasional Tbk lebih besar dari sisi kapitalisasi pasar. Mana yang lebih baik tergantung tujuan investasimu.
| INCI | SCPI | |
|---|---|---|
Kapitalisasi Pasar | 167,16 M | 104,4 M |
Volume | 43,7 rb | — |
Lot | 437 | — |
Perputaran | 34,93 jt | — |
Harga Rata-rata | 799,34 | — |
Nilai Transaksi | 34,93 jt | — |
Harga Ekuilibrium Indikatif | 800 | — |
Volume Ekuilibrium Indikatif | 2 | — |
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Perbandingan imbal hasil
Imbal hasil berjalan pada periode standar
Berita terkini
Berita terbaru kedua aset
Berita terkini
Berita terbaru kedua aset
Tentang Intanwijaya Internasional Tbk
PT Intanwijaya International Tbk (the Company) formerly named as PT Intan Wijaya Chemical Industry Tbk, was established in Jakarta based on the Notarial Deed No. 64 of Jony Frederik Berthold Tumbelaka Sinjal, S.H., dated November 14, 1981.The company's business field in in the Formaldehyde and Formaldehyde Resin Industries with the capacity of 96.000 metrics tons per annum in the form of liquid and 7.000 metric tons per annum in the form of powder and Hexamine 6.000 metric tons per annum.
Selengkapnya di halaman INCI →Tentang Organon Pharma Indonesia Tbk.
PT Merck Sharp Dohme Pharma Tbk was established within the frame work of the Foreign Capital Investment Law No. 1 year 1967 as amended by Law No. 11 year 1970 based on Notarial Deed No. 17 dated 7 March 1972 of Djojo Muljadi, S.H. The company originally incorporated as PT. Essex Indonesia, as a joint venture between Schering Corporation, a worldwide, research-based pharmaceutical enterprise headquartered in the United States, and an Indonesian businessman.
Selengkapnya di halaman SCPI →
